← Eichor
Condition: Metastatic Breast Cancer Mbc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Breast Cancer Mbc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Phase 3 · 73 location(s) · American Society of Clinical Oncology · NCT06377852Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Phase N/A · 40 location(s) · Spanish Breast Cancer Research Group · NCT02819882HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Phase 1/Phase 2 · 1 location(s) · University of Virginia · NCT07441889Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Phase 2 · 1 location(s) · National Taiwan University Hospital · NCT05720260Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metas
Phase N/A · 1 location(s) · European Institute of Oncology · NCT06762483Scalp Cooling in MBC
Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT04986579Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Phase 2 · 3 location(s) · Reshma L. Mahtani, D.O. · NCT06263543Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT06033287Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Phase 3 · 3 location(s) · Shanghai Yizhong Pharmaceutical Co., Ltd. · NCT06143553A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
Phase N/A · 1 location(s) · Menarini Silicon Biosystems, INC · NCT06833853Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastat
NA · 1 location(s) · Washington University School of Medicine · NCT04968964HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
Phase N/A · 1 location(s) · Renske Altena · NCT06830382Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Phase N/A · 1 location(s) · University of California, San Francisco · NCT06774027A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-
Phase 1 · 3 location(s) · ExpreS2ion Biotechnologies · NCT06746688Swedish Ibrance Registries Insights (SIRI)
Phase N/A · 1 location(s) · Pfizer · NCT04654208Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treat
Phase 2 · 5 location(s) · Delcath Systems Inc. · NCT06875128ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast C
Phase 2 · 44 location(s) · ALX Oncology Inc. · NCT07007559Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
Phase 2 · 11 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT04965766A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Phase 1 · 4 location(s) · Janssen Research & Development, LLC · NCT07524855Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Phase 2 · 3 location(s) · Sonya Reid · NCT05693766Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
NA · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06855654Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast Ca
Phase N/A · 5 location(s) · Hellenic Cooperative Oncology Group · NCT07066917Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT06734533HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Phase 2 · 7 location(s) · Abscint NV/SA · NCT06369831EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)
Phase N/A · 1 location(s) · Tel-Aviv Sourasky Medical Center · NCT07646171
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.